OTC Link · Basic Materials · Specialty Chemicals
NOVONESIS B UNSP/ADR
Novozymes delivered a solid H1 beat, with EPS of **$1.27** versus **$0.60** expected and revenue of **$2.6B** topping estimates despite no major catalyst. Growth was modest at 15% EPS and 8% revenue, so this looks like steady execution rather than a reacceleration.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 | H1 2026 | 0.60 | 1.27 | +111.67% | $2.61B | ✅ Beat | — | — | — |
| 2026-02-25 | FY 2025 | — | 1.73 | — | $4.16B | — | — | — | — |
| 2025-08-21 | H1 2025 |
| — |
| 0.88 |
| — |
| $2.38B |
| — |
| — |
| — |
| — |
| 2025-02-26 | FY 2024 | — | 1.39 | — | $4.15B | — | -1.26% | +3.67% | -3.77% |
| 2024-08-27 | H1 2024 | — | 0.69 | — | $2.10B | — | — | — | — |
| 2024-02-01 | Q4 2023 | 0.44 | 0.36 | -18.18% | $664.2M | ❌ Miss | — | — | — |
| 2023-10-26 | Q3 2023 | 0.42 | 0.49 | +16.67% | $650.5M | ✅ Beat | — | — | — |
| 2023-04-26 | Q1 2023 | 0.44 | 0.41 | -6.82% | $666.3M | ❌ Miss | — | — | — |
Showing last 8 quarters.